These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 1434216

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.
    Yanagawa H, Sone S, Munekata M, Atagi S, Nii A, Ogura T.
    Clin Exp Immunol; 1992 May; 88(2):207-12. PubMed ID: 1315227
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI.
    J Immunol; 1989 Dec 15; 143(12):4282-6. PubMed ID: 2512355
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC, Owen-Schaub LB, Roth JA, Grimm EA.
    Cancer Res; 1990 Jun 15; 50(12):3526-32. PubMed ID: 2160321
    [Abstract] [Full Text] [Related]

  • 28. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
    Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS.
    Bone Marrow Transplant; 2003 Jul 15; 32(2):177-86. PubMed ID: 12838283
    [Abstract] [Full Text] [Related]

  • 29. [Clinical significance of cytokine measurement in pleural effusion].
    Naito T, Ohtsuka M, Ishikawa H, Satoh H, Hasegawa S.
    Kekkaku; 1997 Oct 15; 72(10):565-72. PubMed ID: 9386355
    [Abstract] [Full Text] [Related]

  • 30. Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors.
    Dilloo D, Laws HJ, Hanenberg H, Körholz D, Nürnberger W, Burdach SE.
    Exp Hematol; 1994 Oct 15; 22(11):1081-8. PubMed ID: 7925775
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of interferon-gamma, interferon-gamma-inducing cytokines, and interferon-gamma-inducible chemokines in tuberculous pleural effusions.
    Okamoto M, Kawabe T, Iwasaki Y, Hara T, Hashimoto N, Imaizumi K, Hasegawa Y, Shimokata K.
    J Lab Clin Med; 2005 Feb 15; 145(2):88-93. PubMed ID: 15746651
    [Abstract] [Full Text] [Related]

  • 32. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
    Blanchard DK, Kavanagh JJ, Sinkovics JG, Cavanagh D, Hewitt SM, Djeu JY.
    Cancer Res; 1988 Nov 15; 48(22):6321-7. PubMed ID: 2972357
    [Abstract] [Full Text] [Related]

  • 33. Intrapleural application of natural IFN alpha in breast cancer patients with pleural carcinomatosis. Monitoring of immunotherapy by assaying serum interferon levels.
    Mazuran R, Ikić-Sutlić M, Jereb B, Stabuc B, Krasovec MU, Cerar O, Soos E.
    J Biol Regul Homeost Agents; 1992 Nov 15; 6(2):46-52. PubMed ID: 1414464
    [Abstract] [Full Text] [Related]

  • 34. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
    Suzuki H, Abo S, Kitamura M, Hashimoto M, Izumi K.
    Surg Today; 1993 Nov 15; 23(12):1053-9. PubMed ID: 8118118
    [Abstract] [Full Text] [Related]

  • 35. Macrophage colony-stimulating factor activity in malignant pleural effusions. Its augmentation by intrapleural interleukin-2 infusions.
    Sone S, Nakanishi M, Ohmoto Y, Yanagawa H, Ogura T.
    Chest; 1991 Feb 15; 99(2):377-81. PubMed ID: 1989799
    [Abstract] [Full Text] [Related]

  • 36. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
    Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, Perng RP.
    Chest; 1997 Oct 15; 112(4):960-6. PubMed ID: 9377959
    [Abstract] [Full Text] [Related]

  • 37. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
    Takahashi K, Sone S, Kimura S, Ogura T, Monden Y.
    Chest; 1993 Jun 15; 103(6):1732-8. PubMed ID: 8404092
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
    Takahashi K, Sone S, Saito S, Kamamura Y, Uyama T, Ogura T, Monden Y.
    Jpn J Cancer Res; 1995 Sep 15; 86(9):861-6. PubMed ID: 7591964
    [Abstract] [Full Text] [Related]

  • 40. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
    Liu X, Li D, Zhang C, Ba D, Liu J, Wan T, Li Z, Jin Y, He Y.
    Chin Med Sci J; 1993 Sep 15; 8(3):186-9. PubMed ID: 8142637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.